Catalyst
Slingshot members are tracking this event:
PDUFA date for Biomarin's (BMRN) VOXZOGO (Vosoritide) in Achondroplasia extended by three months to November 20, 2021
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BMRN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 19, 2021
Occurred Source:
https://investors.biomarin.com/2021-11-19-BioMarin-Receives-FDA-Approval-for-VOXZOGO-TM-vosoritide-for-Injection,-Indicated-to-Increase-Linear-Growth-in-Children-with-Achondroplasia-Aged-5-and-Up-with-Open-Growth-Plates
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Voxzogo, Vosoritide, Achondroplasia
